Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours

BACKGROUND: AZD2811 is a potent, selective Aurora kinase B inhibitor. We report the dose-escalation phase of a first-in-human study assessing nanoparticle-encapsulated AZD2811 in advanced solid tumours. METHODS: AZD2811 was administered in 12 dose-escalation cohorts (2-h intravenous infusion; 15‒600...

Descripción completa

Detalles Bibliográficos
Autores principales: Johnson, Melissa L., Wang, Judy S., Falchook, Gerald, Greenlees, Carol, Jones, Suzanne, Strickland, Donald, Fabbri, Giulia, Kennedy, Caroline, Elizabeth Pease, J., Sainsbury, Liz, MacDonald, Alexander, Schalkwijk, Stein, Szekeres, Philip, Cosaert, Jan, Burris, Howard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147685/
https://www.ncbi.nlm.nih.gov/pubmed/36871042
http://dx.doi.org/10.1038/s41416-023-02185-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10147685/
https://www.ncbi.nlm.nih.gov/pubmed/36871042
http://dx.doi.org/10.1038/s41416-023-02185-2

Ejemplares similares